Tianda Pharmaceuticals (HKSE:00455) Cash And Cash Equivalents : HK$162.4 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Cash And Cash Equivalents?

Tianda Pharmaceuticals's quarterly cash and cash equivalents declined from Sep. 2022 (HK$232.86 Mil) to Jun. 2023 (HK$189.65 Mil) but then stayed the same from Jun. 2023 (HK$189.65 Mil) to Dec. 2023 (HK$162.44 Mil).

Tianda Pharmaceuticals's annual cash and cash equivalents increased from Mar. 2021 (HK$234.99 Mil) to Mar. 2022 (HK$334.00 Mil) but then declined from Mar. 2022 (HK$334.00 Mil) to Dec. 2023 (HK$162.44 Mil).

Tianda Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Tianda Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Cash And Cash Equivalents Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

384.91

302.02

234.99

334.00

162.44

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															202.23	334.00	232.86	189.65	162.44

Tianda Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Tianda Pharmaceuticals (HKSE:00455) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Tianda Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines